title: Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease.
abstract: Pomegranate juice contains antioxidants such as soluble polyphenols, tannins, and anthocyanins and may have antiatherosclerotic properties. However, no study has investigated the effects of pomegranate juice on patients who have ischemic coronary heart disease (CHD). We investigated whether daily consumption of pomegranate juice for 3 months would affect myocardial perfusion in 45 patients who had CHD and myocardial ischemia in a randomized, placebo-controlled, double-blind study. Patients were randomly assigned into 1 of 2 groups: a pomegranate juice group (240 ml/day) or a placebo group that drank a beverage of similar caloric content, amount, flavor, and color. Participants underwent electrocardiographic-gated myocardial perfusion single-photon emission computed tomographic technetium-99m tetrofosmin scintigraphy at rest and during stress at baseline and 3 months. Visual scoring of images using standardized segmentation and nomenclature (17 segments, scale 0 to 4) was performed by a blinded independent nuclear cardiologist. To assess the amount of inducible ischemia, the summed difference score (SDS) was calculated by subtracting the summed score at rest from the summed stress score. The experimental and control groups showed similar levels of stress-induced ischemia (SDS) at baseline (p >0.05). After 3 months, the extent of stress-induced ischemia decreased in the pomegranate group (SDS -0.8 +/- 2.7) but increased in the control group (SDS 1.2 +/- 3.1, p <0.05). This benefit was observed without changes in cardiac medications, blood sugar, hemoglobin A1c, weight, or blood pressure in either group. In conclusion, daily consumption of pomegranate juice may improve stress-induced myocardial ischemia in patients who have CHD.
authors.affiliation: The Preventive Medicine Research Institute, Sausalito, California, USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Sumner
authors.forename: Melanie
authors.initials: M
authors.lastname: Elliott-Eller
authors.forename: Gerdi
authors.initials: G
authors.lastname: Weidner
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Daubenmier
authors.forename: Mailine H
authors.initials: MH
authors.lastname: Chew
authors.forename: Ruth
authors.initials: R
authors.lastname: Marlin
authors.forename: Caren J
authors.initials: CJ
authors.lastname: Raisin
authors.forename: Dean
authors.initials: D
authors.lastname: Ornish
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001628:Beverages; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000178:diet therapy*; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006801:Humans; D029561:Lythraceae; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D008517:Phytotherapy; D028321:Plant Preparations; D019275:Radiopharmaceuticals; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D016896:Treatment Outcome
chemical_list: D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D028321:Plant Preparations; D019275:Radiopharmaceuticals; C078700:technetium tc-99m tetrofosmin